-
A New Type of Drug Approval
At the AACR Annual Meeting, researchers and regulators discuss what it means to tie approval of an immunotherapy to tumors' molecular characteristics, not to their tissues of origin.
by Kate Yandell
-
Non–Small Cell Lung Cancer Takes Center Stage
A trio of clinical trials at the AACR Annual Meeting spotlight new avenues for non-small cell lung cancer treatment.
by Brad Jones
-
Pembrolizumab Shows Further Promise for Melanoma
In a phase III clinical trial, pembrolizumab yielded a 75.4 percent recurrence-free survival rate after 12 months among patients whose stage III melanoma tumors had been fully resected.
by Brad Jones
-
A Better Way to Screen for Lynch Syndrome?
Researchers say a next-generation sequencing test could improve screening in colorectal cancer patients for a hereditary syndrome that raises cancer risk. Some experts have concerns.
by Cheryl Platzman Weinstock
-
Forward Look
Banking on BacteriaResponse to immunotherapy may be linked to gut microbiome.
by Chris Palmer
-
Forward Look
Improving Cancer Care in Sub-Saharan AfricaNew guidelines account for limited medical resources.
by Cameron Walker
-
Forward Look
Treating Early-Stage Lung CancerEfforts are underway to define role of high-dose radiation.
by Stephen Ornes
-
Healthy Habits
Head StartDeveloping healthy behaviors in young adulthood can help reduce cancer risk later in life.
by Brenda Conaway
-
Searching Blood for Cancer Clues
Researchers are developing blood tests that help track and identify molecular changes in tumors. But many hurdles remain before these “liquid biopsies” become standard.
by Stephen Ornes
-
Liver Cancer on the Rise
Liver cancer incidence and death rates are increasing rapidly. Although there is no screening test for the disease, minimizing risk factors—hepatitis B and C, smoking, obesity and type 2 diabetes—could prevent many cases from developing.
by Sue Rochman
Cancer Talk
Treating Smoldering Multiple Myeloma
A monoclonal antibody drug reduced the risk of smoldering myeloma progressing to multiple myeloma in patients at high risk for disease progression.
by Sandra Gordon
Immunotherapy Improves Survival in Bladder CancerNew research indicates that adding immunotherapy to muscle-invasive bladder cancer treatment can improve event-free and overall survival.
by Laura Gesualdi-Gilmore
Cancer Patients Who Quit Smoking, Even Years After Diagnosis, Live LongerFindings from a recent study support smoking cessation after diagnosis, with the most pronounced effect in those who received treatment within six months of diagnosis.
by Kyle Bagenstose
Delaying Treatment ResistanceAdding a CDK 4/6 inhibitor extends progression-free survival for people with metastatic HR-positive, HER2-positive breast cancer.
by Thomas Celona